Bacil Pharma Peer Comparison

BSE: 524516

₹21.44

₹0.78 (3.78%)

As on 18-Sep-2026IST

Market cap

₹31 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

46.8

P/B Ratio

1.2

Div. Yield

0 %

Edit

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	31	33,911	29,031	28,149	27,692
Revenue (₹ Cr)	--	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	0.66	414.00	288.22	387.35	-371.81
Net Margin (%)	204.98	11.23	14.79	26.01	-3.93
RoE (%)	2.57	8.38	29.77	25.18	-3.85
Price to Earnings	46.77	82.91	100.73	72.88	--
Price-To-Book	1.22	6.74	21.63	16.31	3.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	0.00	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	0.32	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	0.16	2,792.00	1,485.56	919.25	8,195.15
EBITDA	-0.16	772.00	450.24	542.56	1,010.13
Depreciation	0.00	226.00	50.83	37.68	857.51
EBIT	-0.16	546.00	399.41	504.88	152.62
Interest	0.00	217.00	40.84	3.77	342.73
Other Income	0.32	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	0.16	463.00	371.35	528.56	-162.68
Provision for Tax	-0.50	49.00	83.14	141.21	209.13
Profit after Tax	0.66	414.00	288.22	387.35	-371.81

Liabilities (₹ Cr)

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	24.81	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	0.00	1,712.00	202.03	42.40	5,044.14
Current Liabilities	2.58	1,622.00	835.87	230.82	4,758.28
Total Liabilities	25.60	8,100.00	1,451.43	1,549.26	15,513.53

Assets (₹ Cr)

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	25.64	5,343.00	519.60	1,026.85	10,211.52
Current Assets	1.75	2,606.00	1,681.81	881.27	7,191.66
Total Assets	25.60	8,100.00	1,451.43	1,549.26	15,513.53
Total Debt*	0.16	1,859.00	393.17	8.18	4,720.27
Net Current Assets	-0.83	984.00	845.94	650.46	2,433.38
Contingent Liabilities	--	770.26	12.25	15.38	99.76

Cashflow (₹ Cr)

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	0.40	-22.00	159.18	118.34	892.30
Cash Flow from Investing Activities	0.34	-783.00	-64.81	-223.94	-477.46
Cash from Financing Activities	2.08	409.00	-39.81	261.12	-440.83
Net Cash Inflow / Outflow	2.82	-396.00	54.56	155.52	-25.99

Ratios

Profitability Ratios

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	3.03	4.07	26.97	20.14	6.61
ROE (%)	2.57	8.38	29.77	25.18	-3.85
ROA (%)	2.48	4.94	24.77	21.93	-2.21
EBIT Margin (%)	--	15.32	20.63	34.54	1.66
Net Margin (%)	204.98	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	--	18.37	46.65	40.90	0.78
EBIT Growth (%)	68.20	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	-56.02	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	-81.95	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	4,204.55	29.77	42.49	94.96	2.28

Valuation Ratios

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	46.77	85.10	99.18	72.88	-88.50
Price / Book Value	1.22	6.74	21.63	16.31	3.46
Dividend Yield (%)	0.00	0.00	0.09	0.07	0.00
EV/EBITDA	-176.60	45.82	64.29	51.52	31.51
Market Cap (₹ Cr)	--	23,064.69	0.00	19,988.69	29,731.27

Solvency Ratios

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.01	0.53
Short term debt to equity ratio	0.01	0.11	0.54	0.02	0.12
Current Ratio	0.68	1.61	2.01	3.82	1.51
Quick Ratio	0.68	1.06	1.14	2.82	0.87
Interest Coverage	--	3.13	10.09	141.16	0.53

Operating Efficiency Ratios

	Bacil Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	--	16.50	26.28	24.80	23.44
Asset Turnover	0.00	0.43	1.66	0.83	0.55
Receivable days	--	60.36	47.59	90.06	77.05
Inventory Days	--	64.42	62.58	61.02	77.13
Payable days	--	218.94	228.78	96.06	173.49
Cash Conversion Cycle	--	-94.15	-118.62	55.02	-19.30

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly